{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:24:44Z","timestamp":1789593884880,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clon.2017.10.010","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T21:00:26Z","timestamp":1509483626000},"page":"30-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"D.N.","family":"Cagney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"O'Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.D.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Buckney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2017.10.010_bib1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2017.10.010_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mds024","article-title":"European cancer mortality predictions for the year 2012","volume":"23","author":"Malvezzi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib3","first-page":"225","article-title":"Cancer statistics","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"10.1016\/j.clon.2017.10.010_bib4","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs concurrent chemoradiation for stage III non\u2013small cell lung cancer: randomized Phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.clon.2017.10.010_bib5","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non\u2013small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib6","article-title":"Concurrent chemoradiotherapy in non-small cell lung cancer","volume":"4","author":"Rowell","year":"2004","journal-title":"The Cochrane Library"},{"key":"10.1016\/j.clon.2017.10.010_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0169-5002(99)00019-7","article-title":"Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients","volume":"24","author":"Martel","year":"1999","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2017.10.010_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2001.19.1.127","article-title":"Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial","volume":"19","author":"Hayman","year":"2001","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clon.2017.10.010_bib9","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1200\/JCO.2004.02.165","article-title":"Carboplatin\/paclitaxel or carboplatin\/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium","volume":"22","author":"Marks","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijrobp.2006.11.051","article-title":"High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer","volume":"68","author":"Zhao","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2017.10.010_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(97)06305-8","article-title":"Parmar M on behalf of CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial","volume":"350","author":"Saunders","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2017.10.010_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0167-8140(00)00160-2","article-title":"Updated data for CHART in NSCLC: further analyses","volume":"55","author":"Bentzen","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib13","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1200\/JCO.2004.02.165","article-title":"Carboplatin\/paclitaxel or carboplatin\/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium","volume":"22","author":"Marks","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib14","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.1200\/JCO.2005.22.319","article-title":"Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin\/paclitaxel in patients with early-stage (I\/II) non-small-cell lung cancer: long-term results of a phase II study","volume":"23","author":"Jeremi\u0107","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.radonc.2009.04.002","article-title":"A\u00a0phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer","volume":"93","author":"Jenkins","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijrobp.2007.09.048","article-title":"HI-CHART: a phase I\/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small cell lung cancer","volume":"71","author":"De Ruysscher","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2017.10.010_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0360-3016(00)01374-2","article-title":"A\u00a0new approach to dose escalation in non-small-cell lung cancer","volume":"49","author":"Mehta","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.clon.2017.10.010_bib18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1399-6576.1996.tb04530.x","article-title":"The Helsinki declaration, research guidelines and regulations: present and future editorial aspects","volume":"40","author":"Dale","year":"1996","journal-title":"Acta Anaesthesiol Scand"},{"issue":"7","key":"10.1016\/j.clon.2017.10.010_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/oxfordjournals.annonc.a059286","article-title":"Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer","volume":"6","author":"Armstrong","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib20","series-title":"Radiation morbidity scoring criteria","year":"1995"},{"key":"10.1016\/j.clon.2017.10.010_bib21","series-title":"Radiation morbidity schema","author":"European Organization for Research and Treatment of Cancer","year":"1995"},{"key":"10.1016\/j.clon.2017.10.010_bib22","series-title":"Pulmonary toxicity schema","year":"1992"},{"key":"10.1016\/j.clon.2017.10.010_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2004.06.014","article-title":"Dosimetric and clinical predictors for radiation-induced esophageal injury","volume":"61","author":"Ahn","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2017.10.010_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0360-3016(02)03937-8","article-title":"Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy","volume":"55","author":"Singh","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2017.10.010_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0360-3016(99)00163-7","article-title":"Clinical and dosimetric predictors of radiation-induced esophageal toxicity","volume":"45","author":"Maguire","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2017.10.010_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JTO.0b013e3181915028","article-title":"Late complications of high-dose (>\/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer","volume":"4","author":"Lee","year":"2009","journal-title":"J\u00a0Thoracic Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0360-3016(02)02793-1","article-title":"Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04","volume":"53","author":"Komaki","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2017.10.010_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clon.2008.10.003","article-title":"Oesophageal toxicity and hypo-fractionated concurrent chemoradiotherapy for non-small cell lung cancer","volume":"21","author":"Tho","year":"2009","journal-title":"Clin Oncol"},{"issue":"14_suppl","key":"10.1016\/j.clon.2017.10.010_bib29","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1200\/jco.2004.22.90140.7233","article-title":"Intensity modulated radiation therapy (IMRT) may reduce the oesophageal toxicity of hypofractionated accelerated 3-D radiation for non small cell lung carcinoma","volume":"22","author":"Thirion","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.clon.2017.10.010_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.clon.2017.10.010_bib31","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1200\/JCO.2012.41.6677","article-title":"Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis","volume":"30","author":"Mauguen","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2017.10.010_bib32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2006.09.005","article-title":"Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)","volume":"43","author":"Belderbos","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2017.10.010_bib33","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.ejca.2014.07.009","article-title":"SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status","volume":"50","author":"Maguire","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2017.10.010_bib34","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijrobp.2008.10.020","article-title":"A\u00a0phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study","volume":"74","author":"Cho","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2017.10.010_bib35","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/cncr.21007","article-title":"Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma","volume":"103","author":"Rosenzweig","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2017.10.010_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0167-8140(01)00425-X","article-title":"Curative radiotherapy for a second primary lung cancer arising after pneumonectomy \u2013techniques and results","volume":"62","author":"Lagerwaard","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2017.10.010_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clon.2008.12.011","article-title":"Escalation and intensification of radiotherapy for stage 3 non-small cell lung cancer: opportunities for treatment improvement","volume":"21","author":"Fenwick","year":"2009","journal-title":"Clin Oncol"},{"issue":"7","key":"10.1016\/j.clon.2017.10.010_bib38","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose\u00a0radiotherapy in poor-risk patients with \u201cultracentral\u201d non\u2013small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655517304442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655517304442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:44:34Z","timestamp":1760543074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655517304442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0936655517304442"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2017.10.010","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2017.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}